Developing Cell Therapies for a Range of Diseases
Celularity is investigating allogeneic cell therapies that are ready-to-use and eliminate the need for matching patients with donors.
We already have a number of products in clinical trials for hematological cancers and solid tumors as well as allergy and autoimmune diseases, even though we are only in the early stages of unlocking the full potential of our disruptive IMPACT™ platform
CYNK-001: Placental-derived Natural Killer (PNK) Cells
We are investigating CYNK-001 in the clinic as a treatment for multiple cancer indications—multiple myeloma (MM), acute myeloid lymphoma (AML), and glioblastoma multiforme (GBM)—as well as for the emerging infectious disease, COVID-19.
CYNK-001 is manufactured from a specific type of immune cell, natural killer (NK) cells, that we extract from postpartum placentas. A normal part of the innate immune system, NK cells recognize and kill tumor cells as well as virally-infected cells.
Preclinical studies show that CYNK-001 displays cell killing activity against MM cells, AML cells, GBM cells, and SARS-CoV-2-infected cells in vitro. We are investigating CYNK-001 in vivo and expect it to work by augmenting the body’s natural immune response.
Acute Myeloid Leukemia
Program Objective
Achieve durable response for newly diagnosed AML patients in frontline setting
Target Population
Newly diagnosed AML patients
Global Incidence in 2019
40,000 new AML cases
Multiple Myeloma
Program Objective
Achieve durable response for MM patients eligible for ASCT in frontline setting
Target Population
Newly diagnosed MM patients following stem cell transplant
Global Incidence in 2019
70,000 new MM patients
Glioblastoma Multiforme
Coming Soon
Program Objective
Stabilize disease to prevent progression
Target Population
GBM patients
Global Incidence in 2019
37,000 new GBM patients
COVID-19
Program Objective
Limiting viral replication and eliminating infected cells
Target Population
COVID-19 patients
Global Incidence in 2019
Achieve durable response for newly diagnosed AML patients in frontline setting
CYNK-101: Genetically-modified PNK Cells
We are developing CYNK-101 as a combination treatment for multiple cancer indications. CYNK-101 is manufactured from a specific type of immune cell, NK cells, that we extract from postpartum placentas and then genetically engineer to increase cell killing activity when introduced together with an antibody-based anti-cancer treatment.
Preclinical studies show that CYNK-101 plus an antibody therapeutic displays cell killing activity against lymphoma cells in vitro. We expect CYNK-101 to work in vivo by augmenting antibody-dependent cytotoxicity (ADCC), increasing the efficacy of already-approved antibody therapeutics.
We are also engineering PNKs to directly recognize tumor cells even in the absence of the appropriate signals by expressing chimeric antigen receptors (CARs) on their surface. This enhances anti-tumor activity even when tumors express high levels of inhibitory ligands.
Placental-derived adherent cells (PDAC)
Overactive or mis-directed immune responses can lead to a number of inflammation-related diseases including allergies and autoimmune disorders.
We are developing placental-derived adherent cells (PDACs) as a treatment against these types of conditions, and have conducted clinical studies in Crohn’s Disease, diabetic foot ulcers, and diabetic peripheral neuropathy.
Preclinical studies show that PDACs modulate the immune response in vitro through effects on T cells, dendritic cells, and macrophages. In vitro studies also show that PDACs enhance neurogenesis, angiogenesis and muscle regeneration.
Placental Exosomes (pEXO)
Exosomes—small, membrane-bound vesicles produced by every cell type tested—are increasingly being studied for their ability to deliver proteins, nucleic acids, and metabolites to target cells.
We are developing placental exosomes (pEXO) as potential treatments that can deliver pro-regenerative factors that promote development of neural cells, blood vessels, and muscle.
Placental-derived T cells
Several CAR-T cell therapies have already been approved by the FDA, but these treatments all require extraction and processing of a patient’s own cells, an expensive and non-scalable process.
Celularity is developing placental-derived CAR-T cells as an allogeneic cell therapy that can be used without the need to match patient with donor.
